The invention
Targeted therapy impairing oncogenic KRAS signalling by inhibition of KRAS–PDEDelta interaction
The invention
- Name of invention
- Targeted therapy impairing oncogenic KRAS signalling by inhibition of KRAS–PDEDelta interaction
- Thérapie ciblée altérant la signalisation oncogénique de KRAS par l'inhibition de l'interaction KRAS–PDEDelta
Invention description
- Description
- Anti-cancer drugs targeting PDEDelta, using RFdiffusion, ProteinMPNN, and Alphafold2 to generate peptides. ACP5 (KAPI) shows 80% inhibition in 2D cells and reduces Cisplatin doses, minimizing side effects in combination therapy.
- Video
- Link
INVENTORS
Tsz Yee LI inventor 3700614060_4310
Ho Chit KWAN inventor 3700614060_4298
Sum Yee WONG inventor 3700614060_4292
Information in this online catalogue is based on data received for the Event and updated by the participant. Catalogue entries remain the sole responsability of the participant. The Exhibition management declines all responsibility for any possible errors or omissions.